glp 1 meds and alzheimer's Role of glucagon-like peptide-1 receptor agonists in disease Parkinson's disease | Journal of Biomedical Science He's Betting on a GLP-1

the goal of this study was to develop an AnglV-derived molecule that retained the pro-cognitive/anti-dementia activity of AnglV and Nle'-AnglV but possessed improved pharmacokinetic properties, thus allowing it to penetrate the BBB in sufficient quantities to reach therapeutic levels in the brain

According to research on semaglutide treatment, the average percentage of total body weight loss on a GLP-1 agonist is around 5.9% at 3 months and 10.9% by 6 months

Ignore that part

Still, GLP-1s may also exert anti-inflammatory effects on the central nervous system, reducing brain inflammation, which has been linked with depression and anxiety, Grawert said

Before starting treatment, your provider will review or order: BMI and blood pressure measurement, fasting blood glucose or A1C, lipid profile, kidney and liver function, hormone levels if indicated by your history, and body composition analysis